Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
| Autor: | Danielle E Robinson, M Sanni Ali, Victoria Y Strauss, Leena Elhussein, Bo Abrahamsen, Nigel K Arden, Yoav Ben-Shlomo, Fergus Caskey, Cyrus Cooper, Daniel Dedman, Antonella Delmestri, Andrew Judge, Muhammad Kassim Javaid, Daniel Prieto-Alhambra |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Health Technology Assessment, Vol 25, Iss 17 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1366-5278 2046-4924 |
| DOI: | 10.3310/hta25170 |
| Popis: | Background: Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects. Objectives: The aims of each work package were as follows. Work package 1: to study the relationship between bisphosphonate use and chronic kidney disease progression. Work package 2: to study the association between using bisphosphonates and fracture risk. Work package 3: to determine the risks of hypocalcaemia, hypophosphataemia, acute kidney injury and upper gastrointestinal events associated with using bisphosphonates. Work package 4: to investigate the association between using bisphosphonates and changes in bone mineral density over time. Design: This was a new-user cohort study design with propensity score matching. Setting and data sources: Data were obtained from UK NHS primary care (Clinical Practice Research Datalink GOLD database) and linked hospital inpatient records (Hospital Episode Statistics) for work packages 1–3 and from the Danish Odense University Hospital Databases for work package 4. Participants: Patients registered in the data sources who had at least one measurement of estimated glomerular filtration rate of |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|